PLoS ONE (Jan 2014)

Genital human papillomavirus infection among women in Bangladesh: findings from a population-based survey.

  • Quamrun Nahar,
  • Farhana Sultana,
  • Anadil Alam,
  • Jessica Yasmine Islam,
  • Mustafizur Rahman,
  • Fatema Khatun,
  • Nazmul Alam,
  • Sushil Kanta Dasgupta,
  • Lena Marions,
  • Ashrafunnessa,
  • Mohammed Kamal,
  • Alejandro Cravioto,
  • Laura Reichenbach

DOI
https://doi.org/10.1371/journal.pone.0107675
Journal volume & issue
Vol. 9, no. 10
p. e107675

Abstract

Read online

BackgroundThere has been no population-based study on human papillomavirus (HPV) prevalence or its genotypes in Bangladesh; a country eligible for GAVI funding for HPV vaccine.MethodsWe used baseline survey data of a prospective cohort study that was conducted in one urban and one rural area of Bangladesh. A total of 997 urban and 905 rural married women, aged 13 to 64 years, were enrolled in the baseline during July-December, 2011. Information was collected on socio-demographic characteristics and potential risk factors for HPV infection followed by gynecological examination and collection of endocervical samples using the cervical cytobrush (Digene cervical sampler). HPV DNA testing was done by Polymerase Chain Reaction (PCR) using a consensus primer set.ResultsPrevalence of any HPV infection was 7.7% with no significant difference between urban and rural women. Most common high-risk genotypes were HPV16, HPV66, HPV18, HPV45, HPV31 and HPV53. Urban women working as housemaids or garment workers were at higher risk of any HPV infection (OR = 2.15, 95% CI: 1.13-4.11) compared to housewives. Rural women whose husband lived overseas were almost two times more likely to have any HPV infection (OR = 1.93; 95% CI 1.05-3.55) compared to women whose husbands lived with them.ConclusionThe prevalence of HPV infection among Bangladeshi women is similar to other regions of Asia. However, type-specific patterns are different. The study findings will inform the formulation of HPV vaccination policies in Bangladesh, monitoring the impact of vaccination programmes, and the identification of target populations for screening.